An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Harvey Pass, M.D.
New York University Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rush University Medical Center
Chicago, Illinois, United States
Not, yet, recruiting - University of Chicago
Chicago, Illinois, United States
Hedy Kindler, M.D.Recruiting - New York University Cancer Center
New York, New York, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2008
- Primary completion
- —
- Completion
- —
- Last update posted
- 28 May 2008
- Registered enrollment
- 90
- Registry id
- NCT00685204
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.